CTOs on the Move

BioReference

www.bioreference.com

 
BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women`s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world. Our client retention is unparalleled in the industry because we are much more than just the provider of quality diagnostics. We have grown primarily as a result of our differentiating business model which ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details
Michael Molinaro
Chief Information Security Officer Profile

Similar Companies

American Esoteric Laboratories

American Esoteric Laboratories is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prime Medical Imaging

Prime Medical Imaging is a Van Buren, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

International Longevity Centre, Usa

International Longevity Centre, Usa is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Open Mri Of North Fulton Inc

Open Mri Of North Fulton Inc is a Roswell, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiaDexus

Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.